All you need to know about the first drug to fight Alzheimer's disease

On June 7, the US Food and Drug Administration (FDA) approved the approval of the first new drug to treat Alzheimer’s disease in nearly 20 years, during which millions suffered with complications of the disease that reached the point of death, and according to a report published on the Medical Express website, we discuss in the following lines about the most prominent Information about this drug, which is a lifeline for millions of patients around the world.

How was the new American drug developed to treat Alzheimer's disease?

Aducanumab is the first treatment for this disease to use human antibodies to target Alzheimer's-causing proteins called toxic beta-amyloid proteins, which circulate in brain cells and result in memory impairment and other symptoms associated with the disease.

What is the importance of this new American drug and why is it a medical revolution?

This drug is the first drug approved in 22 years for the treatment of Alzheimer's disease, unlike the rest of the drugs that were working to alleviate the symptoms and complications experienced by the patient, but this drug is an effective treatment to combat the disease.

What is the journey of producing a new Alzheimer's drug?

The drug was called aducanumab, which is an acronym for monoclonal antibodies that are similar to the capabilities of the immune system to resist toxic proteins that cause disease, as the American pharmaceutical company Biogen, in cooperation with another Japanese company, succeeded in obtaining rapid approval of the drug from the drug authority, after conducting a procedure A number of clinical trials have proven its effectiveness in disease resistance.

What are the most prominent results of clinical trials of the new drug?

The company conducted several clinical trials that demonstrated the effectiveness of the drug in slowing mental decline in patients, in addition to its effectiveness in reducing harmful masses of plaques in the brain, which also contribute to slowing down dementia.

What is the cost of the property?

The manufacturer explained that the drug would cost about $56,000 for a year of treatment, and said the price would not be raised for four years.

And the American Mark Arcambolt, a realtor from the state of Rhode Island, received the new drug, to be the first person to receive an injection of the new Alzheimer's drug Aducanumab, which is 70 years old.